# EU-1-19-1379_public-assessment-report_20190828_20190828_posaconazole-accord-epar-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
29 May 2019
EMA/354142/2019
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Posaconazole Accord
International non-proprietary name: posaconazole
Procedure No. EMEA/H/C/005005/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
4
1.1. Submission of the dossier.
4
1.2. Steps taken for the assessment of the product
6
2. Scientific discussion
6
2.1. Introduction
6
2.2. Quality aspects
7
2.2.1. Introduction
7
2.2.2. Active substance
7
2.2.3. Finished medicinal product
9
2.2.4. Discussion on chemical, and pharmaceutical aspects
15
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
15
2.2.6. Recommendations for future quality development
15
2.3. Non-clinical aspects
16
2.3.1. Introduction
16
2.3.2. Ecotoxicity/environmental risk assessment
16
2.3.3. Discussion on non-clinical aspects
16
2.3.4. Conclusion on the non-clinical aspects.
16
2.4. Clinical aspects
16
2.4.1. Introduction
16
2.4.2. Pharmacokinetics
17
2.4.3. Additional data
21
2.4.4. Pharmacodynamics
21
2.4.5. Post marketing experience
21
2.4.6. Discussion on clinical aspects.
22
2.4.7. Conclusions on clinical aspects
22
2.5. Risk management plan.
22
2.6. Pharmacovigilance.
23
2.7. Product information
23
2.7.1. User consultation.
23
3. Benefit-risk balance
23
4. Recommendation
25
Assessment report
EMA/354142/2019
Page 2/26
